1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma
| Autor: | Schadendorf, D., Dummer, R., Robert, C., Ribas, A., Sullivan, R.J., Panella, T., Mckean, M.A., Santos, E.S., Brill, K., Polli, A., di Pietro, A., Ascierto, P.A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S902-S902 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|